Remibrutinib

Metabolites - Remibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor developed for the treatment of chronic spontaneous urticaria and other immune-mediated inflammatory conditions. Reference standards of Remibrutinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

No Data Found